Originally posted here:
Nature Communications Publishes Pivotal Data From Albatroz Therapeutics Demonstrating That Inhibiting Calnexin Alleviates Arthritis Symptoms and May...
Related Post
- Harbinger Health Unveils Promising New Data on Early Cancer Detection Platform at AACR 2025 - April 26th, 2025
- Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the... - April 26th, 2025
- Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept... - April 26th, 2025
- ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients... - April 26th, 2025
- Spanios and White Lion Capital LLC Announce Strategic Partnership to Accelerate Drug Development - April 26th, 2025
- Tevogen Bio Announces 2025 Annual Meeting - April 26th, 2025
- Oculis Updates Share Capital - April 26th, 2025
- Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting - April 26th, 2025
- Prelude Announces Presentations at 2025 AACR Annual Meeting - April 26th, 2025
- AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance - April 26th, 2025
- MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 - April 26th, 2025
- Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees - April 26th, 2025
- VitaSeal Reviews (EXPERT OPINION) Does VitaSeal Really Work For Diabetes or Is It Just Hype? (Pros & Cons) - April 26th, 2025
- Gluco6 Reviews (SHOCKING RESULTS) Is This Herbal Formula Control Blood Sugar Effectively or Over Hype? - April 26th, 2025
- Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04, at 2025 World Congress on Osteoarthritis - April 26th, 2025
- GenVivo Highlights GEN-1013: A Novel Delivery of an IL-12 Immunotherapy at the 2025 American Association for Cancer Research (AACR) Annual Meeting - April 26th, 2025
- Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities - April 26th, 2025
- Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in... - April 26th, 2025
- Johnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary... - April 26th, 2025
- IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual... - April 26th, 2025
- INVO Fertility Confirms New Nasdaq Trading Symbol of “IVF” - April 25th, 2025
- Alkeus Pharmaceuticals Announces Presentations of Gildeuretinol Data During the Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May... - April 25th, 2025
- Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference - April 25th, 2025
- Guerbet: Q1 2025 revenue - April 25th, 2025
- PCI Biotech Holding ASA: Annual Report 2024 - April 25th, 2025
- Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million - April 25th, 2025
- Faraday Pharmaceuticals to Host Satellite Symposium at SCAI 2025 on Exploring New Frontiers in Reducing Ischemia-Reperfusion Injury - April 25th, 2025
- Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm... - April 25th, 2025
- Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025 - April 25th, 2025
- Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025 - April 25th, 2025
- Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological... - April 25th, 2025
- FluidForm Bio™ Announces Advance in Bioprinted Tissue Therapies with Landmark Publication in Science Advances - April 25th, 2025
- PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops - April 25th, 2025
- Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025 - April 25th, 2025
- Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO) - April 25th, 2025
- Seer to Report First Quarter 2025 Financial Results on May 13, 2025 - April 25th, 2025
- NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025 - April 25th, 2025
- GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update - April 25th, 2025
- Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 - April 25th, 2025
- Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May - April 25th, 2025
- Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm - April 23rd, 2025
- Andrew Taylor joins Novonesis’ Executive Leadership Team - April 23rd, 2025
- Elite Clinical Network and HealthyU Clinics Announce Strategic Partnership to Expand Access to Clinical Research - April 23rd, 2025
- Digicann Ventures Provides Update Regarding Proposed RTO Transaction - April 23rd, 2025
- Sirona Biochem Announces Debenture Financing - April 23rd, 2025
- Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors - April 23rd, 2025
- Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones - April 23rd, 2025
- Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe... - April 23rd, 2025
- Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025 - April 23rd, 2025
- UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates - April 23rd, 2025
- NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into... - April 23rd, 2025
- OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and... - April 23rd, 2025
- Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS) - April 23rd, 2025
- VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a... - April 23rd, 2025
- Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - April 23rd, 2025
- Cytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts - April 23rd, 2025
- Antag Therapeutics expands senior team to support clinical progress - April 23rd, 2025
- Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS - April 23rd, 2025
- Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers - April 23rd, 2025
- Orion Group Interim Report January–March 2025 - April 23rd, 2025
- Precision Neuroscience Receives FDA Clearance for High-Resolution Cortical Electrode Array - April 19th, 2025
- Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for... - April 19th, 2025
- Psyence Group Announces Share Consolidation - April 19th, 2025
- BVI Medical Announces Approval of Breakthrough Technology: FDA 510(k) Clearance of its Laser Endoscopy Ophthalmic System: Leos™ - April 19th, 2025
- Actum Pharma Expands Executive Team to Launch Enhanced Services Program to Support Biopharma Product Commercialization and Market Success - April 19th, 2025
- Best Testosterone Booster Supplements For Muscle Gain & Increase Testosterone For Men Over 40 Or 50 Over The Counter Pills By (Testo Prime) - April 19th, 2025
- Best Testosterone Boosters for Men Over 40 and 50: TestoPrime Under Review - April 19th, 2025
- Best Testosterone Booster Supplements Canada: TestoPrime for Males Over 40 and 50 (By TestoPrime CA) - April 19th, 2025
- Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility - April 19th, 2025
- TELA Bio to Announce First Quarter 2025 Financial Results - April 19th, 2025
- NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors - April 19th, 2025
- Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC - April 19th, 2025
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 19th, 2025
- Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 - April 19th, 2025
- Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers - April 19th, 2025
- Dipharma Awarded Bronze Medal by Ecovadis for Sustainability - April 19th, 2025
- Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria - April 19th, 2025
- Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU) - April 19th, 2025
- Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application - April 19th, 2025
- 23andMe Provides Update Regarding Court-Supervised Sale Process - April 19th, 2025
Recent Comments